Tocqueville Asset Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$969K Buy
4,486
+134
+3% +$25.6K 0.01% 375
2026
Q1
$798K Sell
4,352
-1,117
-20% -$206K 0.01% 388
2025
Q4
$962K Sell
5,469
-1,082
-17% -$177K 0.01% 386
2025
Q3
$918K Buy
6,551
+964
+17% +$130K 0.01% 376
2025
Q2
$702K Sell
5,587
-1,093
-16% -$136K 0.01% 385
2025
Q1
$914K Sell
6,680
-17,160
-72% -$2.45M 0.01% 351
2024
Q4
$3.65M Sell
23,840
-223,695
-90% -$37.7M 0.06% 209
2024
Q3
$48M Buy
247,535
+27,537
+13% +$5.76M 0.75% 32
2024
Q2
$51M Buy
219,998
+173,798
+376% +$37.8M 0.84% 24
2024
Q1
$9.96M Buy
46,200
+41,690
+924% +$9.76M 0.16% 136
2023
Q4
$1.17M Buy
4,510
+289
+7% +$71K 0.02% 322
2023
Q3
$1.08M Sell
4,221
-8,029
-66% -$2.15M 0.02% 320
2023
Q2
$3.49M Buy
12,250
+14
+0.1% +$4.17K 0.06% 214
2023
Q1
$3.4M Buy
12,236
+176
+1% +$48.7K 0.06% 217
2022
Q4
$3.34M Sell
12,060
-1,761
-13% -$497K 0.06% 230
2022
Q3
$3.69M Sell
13,821
-1,378
-9% -$293K 0.08% 211
2022
Q2
$3.1M Sell
15,199
-5,517
-27% -$1.13M 0.06% 259
2022
Q1
$4.36M Sell
20,716
-15,342
-43% -$3.34M 0.07% 251
2021
Q4
$8.65M Sell
36,058
-31,862
-47% -$8.19M 0.12% 177
2021
Q3
$19.2M Sell
67,920
-301
-0.4% -$98.7K 0.28% 96
2021
Q2
$23.6M Sell
68,221
-25,179
-27% -$7.63M 0.34% 75
2021
Q1
$26.1M Buy
93,400
+4,007
+4% +$1.08M 0.4% 59
2020
Q4
$21.9M Sell
89,393
-24,020
-21% -$6.2M 0.37% 65
2020
Q3
$32.2M Buy
113,413
+214
+0.2% +$59.7K 0.62% 36
2020
Q2
$30.3M Sell
113,199
-39,092
-26% -$11.8M 0.63% 33
2020
Q1
$48.2M Buy
152,291
+16,474
+12% +$5M 1.2% 16
2019
Q4
$40.3M Sell
135,817
-3,769
-3% -$1.05M 0.59% 45
2019
Q3
$32.5M Sell
139,586
-19,472
-12% -$4.53M 0.44% 58
2019
Q2
$37.2M Sell
159,058
-5,896
-4% -$1.36M 0.48% 54
2019
Q1
$39M Buy
164,954
+5,990
+4% +$1.89M 0.52% 52
2018
Q4
$47.8M Sell
158,964
-2,194
-1% -$700K 0.72% 29
2018
Q3
$56.9M Buy
161,158
+1,920
+1% +$661K 0.72% 26
2018
Q2
$46.2M Buy
159,238
+40,038
+34% +$11.3M 0.59% 41
2018
Q1
$32.6M Buy
119,200
+3,153
+3% +$979K 0.42% 66
2017
Q4
$37M Buy
116,047
+3,321
+3% +$1.07M 0.42% 72
2017
Q3
$35.3M Sell
112,726
-2,742
-2% -$812K 0.41% 74
2017
Q2
$31.3M Buy
115,468
+7,317
+7% +$1.93M 0.38% 79
2017
Q1
$29.6M Sell
108,151
-8,123
-7% -$2.3M 0.36% 79
2016
Q4
$33M Sell
116,274
-70,274
-38% -$20.8M 0.42% 62
2016
Q3
$58.4M Sell
186,548
-1,080
-0.6% -$320K 0.7% 39
2016
Q2
$45.4M Buy
187,628
+16,707
+10% +$4.4M 0.54% 47
2016
Q1
$44.5M Buy
170,921
+9,821
+6% +$2.59M 0.59% 44
2015
Q4
$49.4M Buy
161,100
+3,959
+3% +$1.14M 0.67% 29
2015
Q3
$45.9M Buy
157,141
+123,814
+372% +$40.9M 0.61% 34
2015
Q2
$13.5M Buy
33,327
+2,175
+7% +$873K 0.16% 172
2015
Q1
$13.2M Buy
31,152
+6,988
+29% +$2.75M 0.15% 168
2014
Q4
$8.2M Sell
24,164
-3,397
-12% -$1.1M 0.09% 236
2014
Q3
$9.12M Buy
27,561
+4,363
+19% +$1.44M 0.1% 208
2014
Q2
$7.32M Buy
23,198
+155
+0.7% +$46.7K 0.07% 255
2014
Q1
$7.05M Buy
23,043
+3,366
+17% +$1.07M 0.09% 211
2013
Q4
$5.5M Buy
19,677
+7,137
+57% +$1.85M 0.07% 242
2013
Q3
$3.02M Buy
12,540
+3,533
+39% +$791K 0.04% 370
2013
Q2
$1.94M Buy
+9,007
New +$1.92M 0.03% 417

Other funds holding BIIB

Tocqueville Asset Management's BIIB Position: Q2 2026 in Review

Tocqueville Asset Management increased its Biogen (BIIB) stake by 3.1% in Q2 2026, buying an estimated $25.6K and bringing the position to 4,486 shares worth $969K. The position accounts for 0.01% of the portfolio, ranked #375.

Tocqueville Asset Management first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $58.4M in Q3 2016. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Tocqueville Asset Management held 4,486 shares of Biogen worth $969K as of Q2 2026.
  • Tocqueville Asset Management bought 134 Biogen shares in Q2 2026, an estimated $25.6K.
  • Biogen made up 0.01% of Tocqueville Asset Management's portfolio in Q2 2026, its #375 holding.
  • Tocqueville Asset Management first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
  • Tocqueville Asset Management's Biogen position peaked at $58.4M in Q3 2016.
  • 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.